Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.3857
Abstract: Importance Despite standard chemoradiotherapy (CRT), most women with lymph node (LN)-positive cervical cancer experience disease recurrence. Immunotherapy is being investigated in the up-front treatment setting. Objectives To assess the safety of sequential immunotherapy after CRT… read more here.
Keywords: treatment; node positive; cervical cancer; ipilimumab ... See more keywords
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2020.10.004
Abstract: Nivolumab-ipilimumab has become the standard of care in the frontline setting for intermediate-/poor-risk metastatic renal cell carcinoma (mRCC). This regimen is associated with survival improvement but significant toxicity. Anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1)… read more here.
Keywords: renal cell; analysis; ipilimumab; prior anti ... See more keywords
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment☆
Sign Up to like & getrecommendations! Published in 2017 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2017.03.029
Abstract: Background Ipilimumab (IPI) and BRAF inhibitors (BRAFi) improve survival in melanoma, but not all patients will benefit and toxicity can be significant. Pretreatment neutrophil to lymphocyte ratio (NLR) has been associated with outcome in IPI-treated… read more here.
Keywords: ipi; treatment; neutrophil lymphocyte; associated outcome ... See more keywords
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0530-6
Abstract: Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB–IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients… read more here.
Keywords: melanoma; pseudo progression; response; talimogene laherparepvec ... See more keywords
Ipilimumab-associated cholestatic hepatitis: a case report and literature review.
Sign Up to like & getrecommendations! Published in 2017 at "Melanoma research"
DOI: 10.1097/cmr.0000000000000366
Abstract: Ipilimumab is a monoclonal antibody that exerts its effects by inhibiting the cytotoxic T-lymphocyte-associated protein 4 receptor on cytotoxic T lymphocytes. It is frequently used for the treatment of unresectable or metastatic melanoma. Ipilimumab may… read more here.
Keywords: cholestatic hepatitis; hepatitis; case; associated cholestatic ... See more keywords
Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
Sign Up to like & getrecommendations! Published in 2019 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000593
Abstract: Ipilimumab is approved for adjuvant melanoma treatment at a dose of 10 mg/kg, but its use is limited owing to high toxicity and treatment-associated costs. We retrospectively analyzed 29 patients who underwent complete resection of stage… read more here.
Keywords: adjuvant setting; treatment; ipilimumab; melanoma ... See more keywords
Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study
Sign Up to like & getrecommendations! Published in 2019 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000617
Abstract: We evaluated the efficacy of nivolumab in patients with metastatic uveal melanoma previously untreated with ipilimumab. We performed a retrospective study at the National Cancer Center Hospital in Tokyo, Japan, where nivolumab was approved 1 year… read more here.
Keywords: uveal melanoma; response; ipilimumab; metastatic uveal ... See more keywords
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)
Sign Up to like & getrecommendations! Published in 2019 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000653
Abstract: Supplemental Digital Content is available in the text. Approximately, 50% of patients with uveal melanoma develop distant metastasis for which no standard therapy is established. In contrast to cutaneous melanoma, the anti-CTLA-4 antibody ipilimumab showed… read more here.
Keywords: uveal melanoma; radiofrequency ablation; ipilimumab; cohort ... See more keywords
Teriflunomide‐induced psoriasiform changes of fingernails: a new example of paradoxical side effect?
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Dermatology"
DOI: 10.1111/ijd.13742
Abstract: References 1 Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454. 2 O’Day SJ, Hamid O, Urba WJ. Targeting… read more here.
Keywords: cancer; engl med; advanced melanoma; ipilimumab ... See more keywords
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002446
Abstract: Background Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, we report the phase 1 data from… read more here.
Keywords: probody; pacmilimab; solid tumors; pacmilimab ipilimumab ... See more keywords
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005620
Abstract: Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be… read more here.
Keywords: fibrolamellar carcinoma; nivolumab; ipilimumab; treatment ... See more keywords